암 바이오마커 시장 보고서(2026년)

A cancer biomarker is a biological molecule found in blood, tissues, or other bodily fluids that serves as an indicator of normal or abnormal activity and the presence of a specific condition or disease, particularly cancer. These biomarkers are crucial in characterizing alterations within tumors.

The primary types of cancer biomarkers include protein biomarkers, genetic biomarkers, and those utilizing omics technologies, imaging technologies, immunoassay, bioinformatics, and cytogenetics profiling technologies. Protein biomarkers are identifiable markers in a patient's blood that correlate with significant events or signal distinct states in a biological process, such as disease progression. They are employed for accurate disease diagnosis. Cancer biomarkers find applications in various cancer types, including breast cancer, lung cancer, colorectal cancer, prostate cancer, thyroid cancer, kidney cancer, and others. These biomarkers are utilized in diagnostics, research and development, prognostics, risk assessment, and various other applications.

Tariffs are influencing the cancer biomarker market by increasing costs of imported reagents, diagnostic instruments, sequencing platforms, imaging equipment, and analytical software. Research institutes and diagnostic laboratories in North America and Europe are most affected due to reliance on imported high-value consumables, while Asia-Pacific faces higher costs for export-oriented assay production. These tariffs are raising testing costs and affecting research budgets. However, they are also encouraging domestic reagent manufacturing, regional technology development, and localized diagnostic innovation.

The cancer biomarker market research report is one of a series of new reports from The Business Research Company that provides cancer biomarker market statistics, including cancer biomarker industry global market size, regional shares, competitors with a cancer biomarker market share, detailed cancer biomarker market segments, market trends and opportunities, and any further data you may need to thrive in the cancer biomarker industry. This cancer biomarker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer biomarker market size has grown rapidly in recent years. It will grow from $25.09 billion in 2025 to $29.07 billion in 2026 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to increasing cancer prevalence worldwide, advancements in molecular biology research, expansion of oncology research funding, rising adoption of biomarker-based diagnostics, improvements in imaging and assay technologies.

The cancer biomarker market size is expected to see rapid growth in the next few years. It will grow to $52.63 billion in 2030 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period can be attributed to increasing demand for personalized oncology treatments, rising investments in precision medicine, expansion of biomarker-driven drug development, growing use of ai-based biomarker analysis, increasing focus on early-stage cancer screening. Major trends in the forecast period include increasing use of genetic and protein biomarkers, rising adoption of companion diagnostics, growing integration of omics technologies, expansion of liquid biopsy applications, enhanced focus on early cancer detection.

The increasing incidence of cancer is fueling the expansion of the cancer biomarker market. Cancer incidence refers to the number of newly diagnosed cases of a particular cancer type within a defined population over a specific period, typically expressed as cases per 100,000 individuals at risk. The growing burden of cancer is driving broader adoption of cancer biomarkers, as they support disease risk assessment, screening for hidden primary tumors, differentiation between benign and malignant conditions, and distinction among different malignancy types. Cancer biomarkers play a critical role in early detection, accurate diagnosis, and ongoing monitoring of cancer by signaling the presence or progression of disease, thereby enabling personalized therapies and improving patient outcomes. For example, in May 2024, a report published by the International Agency for Research on Cancer (IARC) stated that approximately 20 million new cancer cases were recorded globally in 2022, leading to 9.7 million deaths, and projections indicate that new cancer cases could exceed 35 million by 2050, reflecting a 77% increase compared to 2022. As a result, the rising incidence of cancer is expected to drive the growth of the cancer biomarker market in the coming years.

Leading companies in the cancer biomarker market are focusing on developing cutting-edge solutions, such as AI-powered cancer biomarkers, to improve diagnostic precision and tailor treatment plans for patients. AI-powered cancer biomarkers are biological indicators of cancer that are identified and analyzed using advanced artificial intelligence technologies. For example, in September 2023, Ibex Medical Analytics, a US-based company, introduced Galen Breast HER2, an AI-powered solution aimed at improving the accuracy and consistency of HER2 scoring in breast cancer patients. This innovative platform assists pathologists by automatically detecting invasive tumor regions and quantifying HER2 expression in accordance with the 2018 ASCO/CAP guidelines. The Galen Breast HER2 system uses a novel computational process to analyze immunohistochemistry (IHC)-stained slides, offering detailed visual representations of staining patterns and helping pathologists make more informed treatment decisions.

In June 2025, Illumina Inc., a United States-based genomics and sequencing technology company, acquired SomaLogic Inc. for USD 350 million, along with up to USD 75 million in performance-based milestone payments. This acquisition is intended to strengthen Illumina's multi-omics strategy by incorporating high-throughput proteomics and biomarker discovery capabilities into its sequencing ecosystem. SomaLogic Inc., a United States-based clinical diagnostics company, specializes in proteomics and has developed the SomaScan platform, a robust protein biomarker discovery solution used for advanced research and disease profiling.

Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMerieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.

North America was the largest region in the cancer biomaker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cancer biomarker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cancer biomarker market consists of sales of epigenetic biomarkers, and metabolic biomarkers for various cancers such as melanoma, leukemia, bladder cancer, non-hodgkin's lymphoma, endometrial cancer, pancreatic cancer, and liver cancer. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Biomarker Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cancer biomarker market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer biomarker ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer biomarker market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Biomarker Type: Protein Biomarkers; Genetic Biomarkers; Other Biomarker Types
• 2) By Profiling Technologies: Omics Technologies; Immunoassay; Bioinformatics; Cytogenetics
• 3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Thyroid Cancer; Kidney Cancer; Other Cancers
• 4) By Application: Diagnostics; Research And Development; Prognostics; Risk Assessment; Other Applications
• Subsegments:
• 1) By Protein Biomarkers: Tumor-Specific Antigens; Circulating Tumor Protein
• 2) By Genetic Biomarkers: DNA Mutations; RNA Expression Profiles
• 3) By Other Biomarker Types: Epigenetic Biomarkers; Metabolomic Biomarkers
• Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; QIAGEN NV; Illumina Inc.; Bio-Rad Laboratories Inc.; Abbott Laboratories; bioMerieux SA; Becton Dickinson and Company; Merck & Co. Inc.; Bristol-Myers Squibb Company; PerkinElmer Inc.; Siemens AG; Exact Sciences Corporation; Novartis AG; Agilent Technologies Inc.; Hologic Inc.; Myriad Genetics Inc.; Foundation Medicine Inc.; Guardant Health Inc.; Natera Inc.; Sysmex Corporation; Biocartis Group NV; NanoString Technologies Inc.; Veracyte Inc.; Epic Sciences Inc.; Cynvenio Biosystems Inc.; Genomic Health Inc.; Oncocyte Corporation; Exosome Diagnostics Inc.; Grail Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Cancer Biomarker Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Cancer Biomarker Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Cancer Biomarker Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Cancer Biomarker Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Increasing Use Of Genetic And Protein Biomarkers
  • 4.2.2 Rising Adoption Of Companion Diagnostics
  • 4.2.3 Growing Integration Of Omics Technologies
  • 4.2.4 Expansion Of Liquid Biopsy Applications
  • 4.2.5 Enhanced Focus On Early Cancer Detection

5. Cancer Biomarker Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Diagnostic Laboratories
• 5.3 Research Institutes
• 5.4 Pharmaceutical Companies
• 5.5 Biotechnology Firms

6. Cancer Biomarker Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Cancer Biomarker Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Cancer Biomarker PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Cancer Biomarker Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Cancer Biomarker Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Cancer Biomarker Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Cancer Biomarker Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Cancer Biomarker Market Segmentation

• 9.1. Global Cancer Biomarker Market, Segmentation By Biomarker Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types
• 9.2. Global Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Omics Technologies, Immunoassay, Bioinformatics, Cytogenetics
• 9.3. Global Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers
• 9.4. Global Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications
• 9.5. Global Cancer Biomarker Market, Sub-Segmentation Of Protein Biomarkers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tumor-Specific Antigens, Circulating Tumor Protein
• 9.6. Global Cancer Biomarker Market, Sub-Segmentation Of Genetic Biomarkers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• DNA Mutations, RNA Expression Profiles
• 9.7. Global Cancer Biomarker Market, Sub-Segmentation Of Other Biomarker Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Epigenetic Biomarkers, Metabolomic Biomarkers

10. Cancer Biomarker Market Regional And Country Analysis

• 10.1. Global Cancer Biomarker Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Cancer Biomarker Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Cancer Biomarker Market

• 11.1. Asia-Pacific Cancer Biomarker Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Cancer Biomarker Market

• 12.1. China Cancer Biomarker Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Cancer Biomarker Market

• 13.1. India Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Cancer Biomarker Market

• 14.1. Japan Cancer Biomarker Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Cancer Biomarker Market

• 15.1. Australia Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Cancer Biomarker Market

• 16.1. Indonesia Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Cancer Biomarker Market

• 17.1. South Korea Cancer Biomarker Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Cancer Biomarker Market

• 18.1. Taiwan Cancer Biomarker Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Cancer Biomarker Market

• 19.1. South East Asia Cancer Biomarker Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Cancer Biomarker Market

• 20.1. Western Europe Cancer Biomarker Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Cancer Biomarker Market

• 21.1. UK Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Cancer Biomarker Market

• 22.1. Germany Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Cancer Biomarker Market

• 23.1. France Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Cancer Biomarker Market

• 24.1. Italy Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Cancer Biomarker Market

• 25.1. Spain Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Cancer Biomarker Market

• 26.1. Eastern Europe Cancer Biomarker Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Cancer Biomarker Market

• 27.1. Russia Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Cancer Biomarker Market

• 28.1. North America Cancer Biomarker Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Cancer Biomarker Market

• 29.1. USA Cancer Biomarker Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Cancer Biomarker Market

• 30.1. Canada Cancer Biomarker Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Cancer Biomarker Market

• 31.1. South America Cancer Biomarker Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Cancer Biomarker Market

• 32.1. Brazil Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Cancer Biomarker Market

• 33.1. Middle East Cancer Biomarker Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Cancer Biomarker Market

• 34.1. Africa Cancer Biomarker Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Cancer Biomarker Market, Segmentation By Biomarker Type, Segmentation By Profiling Technologies, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Cancer Biomarker Market Regulatory and Investment Landscape

36. Cancer Biomarker Market Competitive Landscape And Company Profiles

• 36.1. Cancer Biomarker Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Cancer Biomarker Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Cancer Biomarker Market Company Profiles
  • 36.3.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. QIAGEN NV Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Cancer Biomarker Market Other Major And Innovative Companies

• Abbott Laboratories, bioMerieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc.

38. Global Cancer Biomarker Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Cancer Biomarker Market

40. Cancer Biomarker Market High Potential Countries, Segments and Strategies

• 40.1 Cancer Biomarker Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Cancer Biomarker Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Cancer Biomarker Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer